BACKGROUND: Few germline BRCA2 rearrangements have been described compared with the large number of germline rearrangements reported in the BRCA1 gene. However, some BRCA2 rearrangements have been reported in families that included at least one case of male breast cancer. OBJECTIVE: To estimate the contribution of large genomic rearrangements to the spectrum of BRCA2 defects. METHODS: Quantitative multiplex PCR of short fluorescent fragments (QMPSF) was used to screen the BRCA2 gene for germline rearrangements in highly selected families. QMPSF was previously used to detect heterozygous deletions/duplications in many genes including BRCA1 and BRCA2. RESULTS: We selected a subgroup of 194 high risk families with four or more breast cancers with an average age at diagnosis of < or = 50 years, who were recruited through 14 genetic counselling centres in France and one centre in Switzerland. BRCA2 mutations were detected in 18.6% (36 index cases) and BRCA1 mutations in 12.4% (24 index cases) of these families. Of the 134 BRCA1/2 negative index cases in this subgroup, 120 were screened for large rearrangements of BRCA2 using QMPSF. Novel and distinct BRCA2 deletions were detected in three families and their boundaries were determined. We found that genomic rearrangements represent 7.7% (95% confidence interval 0% to 16%) of the BRCA2 mutation spectrum. CONCLUSION: The molecular diagnosis of breast cancer predisposition should include screening for BRCA2 rearrangements, at least in families with a high probability of BRCA2 defects.
BACKGROUND: Few germline BRCA2 rearrangements have been described compared with the large number of germline rearrangements reported in the BRCA1 gene. However, some BRCA2 rearrangements have been reported in families that included at least one case of male breast cancer. OBJECTIVE: To estimate the contribution of large genomic rearrangements to the spectrum of BRCA2 defects. METHODS: Quantitative multiplex PCR of short fluorescent fragments (QMPSF) was used to screen the BRCA2 gene for germline rearrangements in highly selected families. QMPSF was previously used to detect heterozygous deletions/duplications in many genes including BRCA1 and BRCA2. RESULTS: We selected a subgroup of 194 high risk families with four or more breast cancers with an average age at diagnosis of < or = 50 years, who were recruited through 14 genetic counselling centres in France and one centre in Switzerland. BRCA2 mutations were detected in 18.6% (36 index cases) and BRCA1 mutations in 12.4% (24 index cases) of these families. Of the 134 BRCA1/2 negative index cases in this subgroup, 120 were screened for large rearrangements of BRCA2 using QMPSF. Novel and distinct BRCA2 deletions were detected in three families and their boundaries were determined. We found that genomic rearrangements represent 7.7% (95% confidence interval 0% to 16%) of the BRCA2 mutation spectrum. CONCLUSION: The molecular diagnosis of breast cancer predisposition should include screening for BRCA2 rearrangements, at least in families with a high probability of BRCA2 defects.
Authors: Frans B L Hogervorst; Petra M Nederlof; Johan J P Gille; Cathal J McElgunn; Maartje Grippeling; Roelof Pruntel; Rein Regnerus; Tibor van Welsem; Resie van Spaendonk; Fred H Menko; Irma Kluijt; Charlotte Dommering; Senno Verhoef; Jan P Schouten; Laura J van't Veer; Gerard Pals Journal: Cancer Res Date: 2003-04-01 Impact factor: 12.701
Authors: Federica Casilli; Zorika Christiana Di Rocco; Sophie Gad; Isabelle Tournier; Dominique Stoppa-Lyonnet; Thierry Frebourg; Mario Tosi Journal: Hum Mutat Date: 2002-09 Impact factor: 4.878
Authors: Erik Teugels; Sylvia De Brakeleer; Guido Goelen; Willy Lissens; Erica Sermijn; Jacques De Grève Journal: Hum Mutat Date: 2005-09 Impact factor: 4.878
Authors: D J Bunyan; D M Eccles; J Sillibourne; E Wilkins; N Simon Thomas; J Shea-Simonds; P J Duncan; C E Curtis; D O Robinson; J F Harvey; N C P Cross Journal: Br J Cancer Date: 2004-09-13 Impact factor: 7.640
Authors: D G R Evans; Mike Bulman; Karen Young; Emma Howard; Stuart Bayliss; Andrew Wallace; Fiona Lalloo Journal: Fam Cancer Date: 2007-07-17 Impact factor: 2.375
Authors: Getachew Boru; Timothy W Grosel; Robert Pilarski; Meredith Stautberg; James B Massengill; Joanne Jeter; Arun Singh; Meghan J Marino; Joseph P McElroy; Frederick H Davidorf; Colleen M Cebulla; Mohamed H Abdel-Rahman Journal: Genes Chromosomes Cancer Date: 2019-04-23 Impact factor: 5.006
Authors: Maurizia Dalla Palma; Susan M Domchek; Jill Stopfer; Julie Erlichman; Jill D Siegfried; Jessica Tigges-Cardwell; Bernard A Mason; Timothy R Rebbeck; Katherine L Nathanson Journal: Cancer Res Date: 2008-08-14 Impact factor: 12.701
Authors: Helena Rudnicka; Tadeusz Debniak; Cezary Cybulski; Tomasz Huzarski; Jacek Gronwald; Jan Lubinski; Bohdan Gorski Journal: Mol Biol Rep Date: 2013-09-25 Impact factor: 2.316
Authors: Menno C van Zelm; Corinne Geertsema; Nicole Nieuwenhuis; Dick de Ridder; Mary Ellen Conley; Claudine Schiff; Ilhan Tezcan; Ewa Bernatowska; Nico G Hartwig; Elisabeth A M Sanders; Jiri Litzman; Irina Kondratenko; Jacques J M van Dongen; Mirjam van der Burg Journal: Am J Hum Genet Date: 2008-02 Impact factor: 11.025
Authors: Maria Santa Rocca; Clara Benna; Elena Goldin; Andrea Di Nisio; Luca De Toni; Ilaria Cosci; Alberto Marchet; Donato Nitti; Carlo Foresta Journal: Mol Med Date: 2021-03-10 Impact factor: 6.354